Longitudinal gut microbiome profiles following tegoprazan, pantoprazole, or no acid-suppressive therapy in patients undergoing percutaneous coronary intervention
This BioProject contains fecal 16S rRNA gene amplicon sequencing data generated in a prospective, randomized, open-label pilot study of patients with angina pectoris undergoing percutaneous coronary intervention and receiving dual antiplatelet therapy. Participants received tegoprazan 50 mg once daily, pantoprazole 40 mg once daily, or no acid-suppressive therapy for 24 weeks. Fecal samples were collected before treatment initiation and at week 24. The V3V4 region of the bacterial 16S rRNA gene was sequenced to characterize longitudinal changes in gut microbial diversity and taxonomic composition and to explore whether these changes differed among the three treatment groups. The dataset comprises paired baseline and week-24 samples from 24 participants.